(S)-4,5,6-四氢-3H-吡咯并[1,2-c]乙二唑1,1-二氧化物 | 132635-95-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 中文名称: (S)-4,5,6-四氢-3H-吡咯并[1,2-c]乙二唑1,1-二氧化物
• 英文名称: (S)-tetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide
• 英文别名: (S)-tetrahydro-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide；(3aS)-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-c]oxathiazole 1,1-dioxide
• CAS: 132635-95-1
• 化学式: C₅H₉NO₃S
• 分子量: 163.197
• InChiKey: WFFHPXGNIIMFHE-YFKPBYRVSA-N

物化性质

• 沸点：
  254.9±23.0 °C(Predicted)
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 储存条件：
  存储条件：2-8°C，密封保存。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : (S)-4,5,6-Tetrahydro-3H-Pyrrolo[1,2-C]Oxathiazole
1,1-Dioxide
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
This substance is not classified as dangerous according to Directive 67/548/EEC.
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 163,2 g/mol
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
No special environmental precautions required.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
No special environmental precautions required.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  (S)-4,5,6-四氢-3H-吡咯并[1,2-c]乙二唑1,1-二氧化物 在 盐酸 、 lithium 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 37.0h， 生成 3-{(2S)-2-[(diphenylphosphino)methyl]pyrrolidin-1-yl}propanoic acid
  参考文献：
  名称：

  洞察金催化机理：溶液中金（i）酰胺络合物的行为†

  摘要：

  我们报道了新的单核和双核金酰胺配合物1-7的合成和活性。双核络合物6b和7通过单晶X射线分析来表征。我们还报告了溶液NMR和凝固点降低实验，以使它们在溶液中的行为合理化，并质疑在金催化中调用的去连接过程。

  DOI：

  10.1039/c3dt33039g
• 作为产物：
  描述：

  2-(R,S)-5-(S)-<3.3.0>-1-aza-2-thia-3-oxabicyclooctane-2-oxide 在 ruthenium(IV) oxide 、 sodium periodate 作用下， 以 氯仿 、 水 为溶剂， 反应 0.17h， 以48%的产率得到(S)-4,5,6-四氢-3H-吡咯并[1,2-c]乙二唑1,1-二氧化物
  参考文献：
  名称：

  某些新型双环亚磺酰胺盐和亚氨基磺酸盐的合成和构型分配

  摘要：

  （S）-脯氨醇和2-（RS）-哌啶-甲醇各自与亚硫酰氯反应，得到一对非对映异构的双环亚酰胺基，其在硫上的构型仅不同。相反，2（RS）-吡咯烷-乙醇和2（RS）-哌啶-乙醇分别与亚硫酰氯反应，得到单一的非对映异构产物。已经确定了这些双环亚磺酰胺的构型，以及衍生自它们的亚磺酰胺的构型。

  DOI：

  10.1016/s0957-4166(00)82280-6

文献信息

• Discovery and optimisation of 1-acyl-2-benzylpyrrolidines as potent dual orexin receptor antagonists
  作者：Jodi T. Williams、John Gatfield、Catherine Roch、Alexander Treiber、Francois Jenck、Martin H. Bolli、Christine Brotschi、Thierry Sifferlen、Bibia Heidmann、Christoph Boss

  DOI：10.1039/c5md00074b

  日期：——

  1-acyl-2-benzylpyrrolidines were discovered as potent and competitive dual orexin receptor antagonists. Metabolic stability was improved to afford oral exposure, and aqueous solubility was increased by twentyfold, providing compounds suitable for preclinical evaluation. Compound 27 showed insurmountable antagonism at both orexin 1 and orexin 2 receptor subtypes and displayed a comparable sleep-promoting

  从在大鼠和人肝微粒体中具有高固有清除率和低水溶性的噻吩并哌啶前导化合物开始，发现了一系列新型的1-酰基-2-苄基吡咯烷酮，它们是有效且具有竞争力的双重orexin受体拮抗剂。改善了代谢稳定性以提供口服暴露，并且水溶性增加了二十倍，从而提供了适合临床前评估的化合物。化合物27对orexin 1和orexin 2受体亚型均显示出不可克服的拮抗作用，并且在大鼠中具有与Almorexant和suvorexant相当的促睡眠作用。
• A [3+3] cyclization strategy for asymmetric synthesis of alkyl substituted piperidine-2-ones using 1,2-cyclic sulfamidates: a formal synthesis of (S)-coniine from l-norvaline
  作者：Abdullah Karanfil、Berrin Balta、Mustafa Eskici

  DOI：10.1016/j.tet.2012.09.081

  日期：2012.12

  β-unsaturated esters after acidic hydrolysis. Hydrogenation of the unsaturated esters and subsequent thermal cyclization afforded the related alkyl substituted piperidine-2-ones. This approach represents a novel [3+3] cyclization strategy for the asymmetric synthesis of alkyl substituted piperidin-2-ones. Efficiency of the cyclization process is illustrated by a formal asymmetric synthesis of (S)-coniine from l-norvaline

  一组代表性的1,2-环氨基磺酸盐与原丙酸三乙酯的区域选择性开环反应在酸性水解后有效地进行，以递送相应的δ-氨基-α，β-不饱和酯。不饱和酯的氢化和随后的热环化提供了相关的烷基取代的哌啶-2-酮。这种方法代表了一种新的[3 + 3]环化策略，用于烷基取代的哌啶-2-酮的不对称合成。由1-正缬氨酸的形式不对称合成（S）-丝氨酸说明了环化过程的效率。
• Combinatorial synthesis of functionalized chiral and doubly chiral ionic liquids and their applications as asymmetric covalent/non-covalent bifunctional organocatalysts
  作者：Long Zhang、Sanzhong Luo、Xueling Mi、Song Liu、Yupu Qiao、Hui Xu、Jin-Pei Cheng

  DOI：10.1039/b713843a

  日期：——

  A facile combinatorial strategy was developed for the construction of libraries of functionalized chiral ionic liquids (FCILs) including doubly chiral ionic liquids and bis-functional chiral ionic liquids. These FCIL libraries have the potential to be used as asymmetric catalysts or chiral ligands. As an example, novel asymmetric bifunctional catalysts were developed by simultaneously incorporating functional groups onto the cation and anion. The resultant bis-functionalized CILs showed significantly improved stereoselectivity over the mono-functionalized parent CILs.

  研究了一种简便的组合策略，用于构建含有双重手性离子液体和双官能团手性离子液体的功能化手性离子液体（FCILs）库。这些FCIL库有望用作不对称催化剂或手性配体。例如，通过同时将官能团引入阳离子和阴离子，开发了新型的不对称双官能团催化剂。由此产生的双官能团化CILs在立体选择性方面显著优于单官能团化母本CILs。
• Imidazolinium sulfonate and sulfamate zwitterions as chiral solvating agents for enantiomeric excess calculations
  作者：Sobia Tabassum、Mazhar Amjad Gilani、René Wilhelm

  DOI：10.1016/j.tetasy.2011.09.018

  日期：2011.9

  synthesis of enantiopure unsymmetrical N-heterocyclic based zwitterions incorporating imidazolinium and alkylsulfonate or sulfamate groups is described. The desired compounds were prepared in good yields from 1,3-propanesultone or cyclic sulfamidates and imidazolines. The imidazolinium based zwitterions proved to be versatile chiral solvating agents for Mosher’s acid, alcohols, cyanohydrins, amino alcohols

  描述了结合咪唑啉鎓和烷基磺酸盐或氨基磺酸盐基团的对映体不对称基于N-杂环的两性离子的合成。由1，3-丙磺酸内酯或环状氨基磺酸酯和咪唑啉以高收率制备所需化合物。咪唑啉鎓基两性离子被证明是通用的手性溶剂化剂，用于Mosher的酸，醇，氰醇，氨基醇，硝基醇，硫醇和羧酸，在1 H和19 F NMR中具有非常高的位移。
• METHODS FOR WOUND HEALING AND SCAR PREVENTION
  申请人：Weinstein David

  公开号：US20170266157A1

  公开（公告）日：2017-09-21

  The present invention is related to a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof. The present invention is further related to a method of healing and/or inhibiting formation of scar tissue in an external wound of a subject comprising topically administering to the external wound of the subject an effective amount of a compositing containing a compound that binds FK506 binding protein 4.

  本发明涉及一种具有式（I）的化合物或其药用可接受的盐或酯。本发明还涉及一种治疗和/或抑制受试者外伤处疤痕组织形成的方法，包括局部给受试者外伤处施用含有结合FK506结合蛋白4的化合物的复合物的有效量。